Objective To investigate the clinical application of angiotensin receptor neprilysin inhibitor Sacubitril/Valsartan in patients with heart failure(HF)，and to provide reference for its standardized use.Methods The electronic medical records of inpatients with HF using Sacubitril/valsartan in cardiovascular medicine department of hospital were collected from hospital information system during Jun.to Sep.2019.Those medical records were analyzed statistically in drug application.Results A total of 73 HF patients were given Sacubitril/valsartan,of which 24 cases(32.88%)were used without indications and 3 cases(4.11%)had contraindications.11 cases(15.07%)had an unreasonable initial treatment dose,9 cases(12.33%)of unreasonable dosing frequency,31 cases(42.47%)of unreasonable conversion with angiotensin converting enzyme inhibitors(ACEI),16 cases(21.92%)of unreasonable conversion with angiotensin receptor blockers(ARB).Conclusion There is a certain gap between clinical application of Sacubitril/Valsartan in HF patients and the requirements of drug instructions and related guidelines for HF,mainly involving indication,usage and dosage,drug conversion.It is recommended to further standardized the clinical application of the drug through pre-prescription review,regular special reviews,strengthening of pharmaceutical care and medical training.